Furthermore, the WNT/β-catenin pathway is strongly linked to androgen/AR-directed therapy and chemotherapy resistance [324,325,326,327], thus WNT signaling presents an attractive therapeutic target for advanced prostate cancer. Here, AR is linked to prostate carcinoma.